They don't dose if there's a problem.
That's why the trial design uses sequential dosing of the first two cohorts.
So second dosing of first cohort means all's well.
I agree we could get a share price pop, especially looking at the valuation variance with Alnylam recently. Traders love this stock if the technical conditions are right.
SP stirring ahead of announcement?, page-6
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)